Bethany Baer, MD

Official, Division of Pharmacovigilance, FDA CBER OBPV

CBER official who questioned Dr. Szarfman's access to VAERS data and acknowledged in 2024 that the RGPS model yielded significantly higher signals than MGPS.

Timeline appearances (16)

Quotes (4)

  • "I understand the theory behind masking and trying to adjust for it, but I feel that comprehending the details of the approach and, importantly, which approach is 'better,' is beyond my training and experience. I think someone with more data mining expertise would have to be involved in that decision."
    Baer wrote to Menschik about Szarfman's 2022 masking paper, conceding that someone with more data mining expertise should make the call between methodologies. · 2024-09-26 view in /quotes/ →
  • "I know that she knows a lot more about data mining than I do!"
    Baer, responding to Zinderman in March 2021, acknowledged Szarfman's superior expertise even while continuing to express concerns about her data mining access. · 2021-03-14 view in /quotes/ →
  • "I know Ana [Szarfman] worked to develop the data mining system"
    Baer wrote in a March 2021 email among FDA CBER officials referring to FDA's current method, recognizing Szarfman's role in building it. · 2021-03 view in /quotes/ →
  • "I know Ana [Szarfman] worked to develop the data mining system and this might be a special circumstance due to her knowledge and experience."
    Baer questioned Szarfman's access to CBER's VAERS data while simultaneously recognizing her unique expertise. · 2021-03-12 view in /quotes/ →